Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry

被引:118
作者
Luk, Andrea O. Y. [1 ]
Ma, Ronald C. W. [1 ]
Lau, Eric S. H. [1 ]
Yang, Xilin [1 ]
Lau, Winnie W. Y. [1 ]
Yu, Linda W. L. [1 ]
Chow, Francis C. C. [1 ]
Chan, Juliana C. N. [1 ,2 ,3 ]
So, Wing-Yee [1 ]
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Hong Kong, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China
关键词
Hb(A1c) variability; type; 2; diabetes; chronic kidney disease; cardiovascular disease; GLYCEMIC VARIABILITY; OXIDATIVE STRESS; GLUCOSE; COMPLICATIONS; HYPERGLYCEMIA;
D O I
10.1002/dmrr.2404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In type 2 diabetes, tight glycaemic control lowers the risk of diabetic complications, but it remains uncertain whether variability of glycaemia influences outcomes. We examined the association of glycated haemoglobin (HbA(1c)) variability with incident chronic kidney disease and cardiovascular disease in a prospective cohort of 8439 Chinese patients with type 2 diabetes recruited from 1994 to 2007. Methods Intrapersonal mean and SD of serially measured HbA(1c) were calculated. Chronic kidney disease was defined as estimated glomerular filtration rate <60ml/min per 1.73m(2). Cardiovascular disease was defined as events of ischemic heart disease, heart failure, ischemic stroke or peripheral vascular disease. Results Over a median follow-up period of 7.2years, 19.7 and 10.0% of patients developed chronic kidney disease and cardiovascular disease, respectively. Patients who progressed to chronic kidney disease had higher mean HbA(1c) (7.8 +/- 1.3% vs 7.4 +/- 1.2%, p<0.001) and SD (1.0 +/- 0.8% vs 0.8 +/- 0.6%, p<0.001) than nonprogressors. Similarly, patients who developed cardiovascular disease had higher mean HbA(1c) (7.7 +/- 1.3% vs 7.4 +/- 1.2%, p<0.001) and SD (1.4 +/- 1.1% vs 1.1 +/- 0.8%, p<0.001) than patients who did not develop cardiovascular disease. By using multivariate-adjusted Cox regression analysis, adjusted SD was associated with incident chronic kidney disease and cardiovascular disease with corresponding hazard ratios of 1.16 (95% CI 1.11-1.22), p<0.001) and 1.27 (95% CI 1.15-1.40, p<0.001), independent of mean HbA(1c) and other confounding variables. Conclusions Long-term glycaemic variability expressed by SD of HbA(1c) predicted development of renal and cardiovascular complications. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 50 条
[21]   HbA1c variability associated with dementia risk in people with type 2 diabetes [J].
Moran, Chris ;
Whitmer, Rachel A. ;
Dove, Zoe ;
Lacy, Mary E. ;
Soh, Yenee ;
Tsai, Ai-Lin ;
Quesenberry, Charles P. ;
Karter, Andrew J. ;
Adams, Alyce S. ;
Gilsanz, Paola .
ALZHEIMERS & DEMENTIA, 2024, 20 (08) :5561-5569
[22]   Diabetes with poor-control HbA1c is cardiovascular disease 'risk equivalent' for mortality: UK Biobank and Hong Kong population-based cohort study [J].
Wan, Eric Yuk Fai ;
Yu, Esther Yee Tak ;
Mak, Ivy Lynn ;
Youn, Hin Moi ;
Chan, Kam Suen ;
Chan, Esther W. Y. ;
Wong, Ian C. K. ;
Lam, Cindy Lo Kuen .
BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (01)
[23]   End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong diabetes registry [J].
Yang, X. L. ;
So, W. Y. ;
Kong, A. P. S. ;
Clarke, P. ;
Ho, C. S. ;
Lam, C. W. K. ;
Ng, M. H. L. ;
Lyu, R. R. ;
Yin, D. D. ;
Chow, C. C. ;
Cockram, C. S. ;
Tong, P. C. Y. ;
Chan, J. C. N. .
DIABETOLOGIA, 2006, 49 (10) :2299-2308
[24]   The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease [J].
Bots, Sophie H. ;
van der Graaf, Yolanda ;
Nathoe, Hendrik M. W. ;
de Borst, Gert Jan ;
Kappelle, Jaap L. ;
Visseren, Frank L. J. ;
Westerink, Jan .
CARDIOVASCULAR DIABETOLOGY, 2016, 15
[25]   Use of thiazolidinedione and cancer risk in Type 2 diabetes: The Hong Kong diabetes registry [J].
Yang, Xilin ;
So, Wing-Yee ;
Ma, Ronald C. W. ;
Yu, Linda W. L. ;
Kong, Alice P. S. ;
Lee, Heung Man ;
Xu, Gang ;
Ozaki, Risa ;
Ko, Gary T. C. ;
Chan, Juliana C. N. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (01) :E11-E15
[26]   Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk [J].
Verhagen, Chloe ;
Janssen, Jolien ;
Minderhoud, Crista A. ;
van den Berg, Esther ;
Wanner, Christoph ;
Passera, Anna ;
Johansen, Odd Erik ;
Biessels, Geert Jan .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (10)
[27]   Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease [J].
De Lima, Jose J. G. ;
Gowdak, Luis Henrique W. ;
David-Neto, Elias ;
Bortolotto, Luiz A. .
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) :159-165
[28]   Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease [J].
Jose J. G. De Lima ;
Luis Henrique W. Gowdak ;
Elias David-Neto ;
Luiz A. Bortolotto .
High Blood Pressure & Cardiovascular Prevention, 2021, 28 :159-165
[29]   Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study [J].
Chu, Lisa ;
Fuller, Mark ;
Jervis, Kathyrn ;
Ciaccia, Antonio ;
Abitbol, Alexander .
CLINICAL THERAPEUTICS, 2021, 43 (09) :1558-+
[30]   HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target [J].
Ceriello, Antonio ;
Lucisano, Giuseppe ;
Prattichizzo, Francesco ;
La Grotta, Rosalba ;
Franzen, Stefan ;
Svensson, Ann-Marie ;
Eliasson, Bjorn ;
Nicolucci, Antonio .
CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)